Scopus
🔓 Açık Erişim
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
BMC Cancer · Aralık 2023
Makale Bilgileri
DergiBMC Cancer
Yayın TarihiAralık 2023
Cilt / Sayfa23
Scopus ID2-s2.0-85147894207
Erişim🔓 Açık Erişim
Özet
Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods: A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results: The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion: Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.
Yazarlar (86)
1
Cengiz Karacin
2
Berna Öksüzoğlu
3
Ayşe Demirci
4
Merve Keskinkilic
5
Naziyet Köse Baytemür
6
Funda Yılmaz
7
Oguzhan Selvi
8
Dilek Erdem
9
Esin Avşar
10
Nail Paksoy
11
Necla Demir
ORCID: 0000-0003-0927-6962
12
Sema Sezgin Goksu
13
Sema Türker
14
Ertuğrul Bayram
15
Abdüssamet Çelebi
16
Hatice Yılmaz
17
Ömer Faruk Kuzu
18
Seda Kahraman
19
İvo Gökmen
20
Abdullah Sakin
21
Ali Alkan
22
Erdinç Nayır
23
Muzafer Uğraklı
24
Ömer Acar
25
İsmail Ertürk
26
Hacer Demir
27
Ferit Aslan
28
Özlem Sönmez
29
Taner Korkmaz
30
Ozde Melisa Celayir
31
Ibrahim Karadag
32
Erkan Kayikcioglu
33
Teoman Sakalar
34
İlker Nihat Öktem
35
Tülay Eren
36
Enes Urul
37
Eda Eylemer Mocan
38
Ziya Kalkan
39
Nilgün Yıldırım
ORCID: 0000-0001-6266-4951
40
Yakup Ergun
ORCID: 0000-0003-4784-6743
41
Baran Akagündüz
42
Serdar Karakaya
43
Engin Kut
44
Fatih Teker
45
Burçin Çakan Demirel
46
Kubilay Karaboyun
47
Elvina Almuradova
48
Olcun Umit Unal
49
Abdilkerim Oyman
50
Deniz Işık
51
Sadi Kerem Okutur
52
Buğra Öztosun
53
Burcu Belen Gülbağcı
54
Mehmet Emin Kalender
55
Elif Şahin
56
Mustafa Seyyar
57
Özlem Özdemir
58
Fatih Selçukbiricik
59
Metin Kanıtez
60
İsa Dede
61
Mahmut Gumus
62
Erhan Gokmen
63
Arzu Yaren
64
Serkan Menekse
65
Senar Ebinç
66
Sercan Aksoy
67
Gökşen İnanç İmamoğlu
68
Mustafa Altınbaş
69
Bülent Çetin
70
Basak Oyan
71
Ozlem Er
72
Nuri Karadurmus
73
Atike Pinar Erdogan
74
Mehmet Artaç
75
Ozgur Tanriverdi
76
Irfan Cicin
77
Mehmet Ali Nahit Sendur
78
Esin Oktay
79
İbrahim Vedat Bayoğlu
80
Semra Paydas
81
Adnan Aydıner
82
Derya Kivrak Salim
83
Caglayan Geredeli
84
Tugba Yavuzsen
85
Mutlu Dogan
86
Ilhan Hacibekiroglu
Anahtar Kelimeler
Advanced breast cancer
Cyclin-dependent kinase
Endocrine treatment
Everolimus
Fulvestrant
Hormonotherapy
Palbociclib
Ribociclib
Kurumlar
Acibadem Hospital
Kayseri Turkey
Acıbadem Mehmet Ali Aydınlar Üniversitesi
Istanbul Turkey
Afyonkarahisar Health Sciences University
Afyonkarahisar Turkey
Akdeniz Üniversitesi
Antalya Turkey
Ankara City Hospital
Ankara Turkey
Ankara Oncology Education and Research Hospital
Ankara Turkey
Ankara Üniversitesi
Ankara Turkey
Antalya Training and Research Hospital
Antalya Turkey
Atatürk Pulmonary Diseases Hospital
Ankara Turkey
Aydin Adnan Menderes University
Aydin Turkey
Batman Training and Research Hospital
Batman Türkiye
Çukurova Üniversitesi
Adana Turkey
Dicle Üniversitesi
Diyarbakir Turkey
Dokuz Eylül Üniversitesi
Izmir Turkey
Dr. Ersin Arslan Training and Research Hospital
Gaziantep Türkiye
Ege Üniversitesi
Izmir Turkey
Erzincan Binali Yıldırım Üniversitesi
Erzincan Turkey
Firat Üniversitesi
Elazig Turkey
Gaziantep Üniversitesi
Gaziantep Turkey
Gülhane Eğitim ve Araştırma Hastanesi
Ankara Turkey
Hacettepe Üniversitesi
Ankara Turkey
Hitit University
Corum Turkey
Istanbul Medeniyet University
Istanbul Turkey
İstanbul Medipol Üniversitesi
Istanbul Turkey
Istanbul Memorial Hospital
Okmeydani Turkey
Istanbul Üniversitesi
Istanbul Turkey
Izmir Tepecik Training and Research Hospital
Izmir Turkey
Kahramanmaraş Necip Fazıl City Hospital
Kahramanmaras Turkey
Kocaeli Üniversitesi
İzmit Turkey
Koç Üniversitesi
Istanbul Turkey
Manisa Celâl Bayar Üniversitesi
Manisa Turkey
Manisa City Hospital
Manisa Turkey
Marmara Üniversitesi
Istanbul Turkey
Meddem Hospital
Isparta Türkiye
Medical Park Hospital
Bursa Turkey
Memorial Hospital
Ankara Turkey
Muğla Sıtkı Koçman Üniversitesi
Mugla Turkey
Mustafa Kemal Üniversitesi
Antakya Turkey
Necmettin Erbakan Üniversitesi
Meram Turkey
Pamukkale Üniversitesi
Denizli Turkey
Prof. Dr. Cemil Tascioglu City Hospital
Istanbul Turkey
Sakarya Üniversitesi
Serdivan Turkey
Süleyman Demirel Üniversitesi
Isparta Turkey
T. C. Sağlık Bakanlığı Ankara Diskapi Yildirim Beyazit Eğitim ve Araştirma Hastanesi
Ankara Turkey
Tekirdağ Namık Kemal Üniversitesi
Tekirdag Turkey
Trakya Üniversitesi
Edirne Turkey
Umraniye Training and Research Hospital
Istanbul Turkey
University of Health Sciences
Istanbul Turkey
VKV Amerikan Hastanesi
Istanbul Turkey
VM Medical Park Kocaeli Hospital
Kocaeli Turkey
Zonguldak State Hospital
Zonguldak Turkey
Metrikler
17
Atıf
86
Yazar
8
Anahtar Kelime